In December 2015 the FDA issued this Drug Safety Communication: “FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections”. In part, it warns about the risk of ketoacidosis, a serious medical condition caused by having too much acid in the blood, for a class of newer diabetes drugs which include Invokana, Farxiga, and Jardiance.
This latest FDA warning about the safety issues associated with these diabetes medicines follows an FDA announcement back in May 2015 about possible need for new drug side effects warnings. We reported about that development in this earlier article, “May 2015 Diabetes Drugs – Ketoacidosis Link Warning By FDA Covers Invokana, Farxiga, And Jardiance, With Label Changes Possible”.
Just a couple of months ago, in October 2015, Health Canada issued this advisory, “Summary Safety Review – Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors INVOKANA (canagliflozin) and FORXIGA (dapagliflozin) – Evaluation of a Potential Risk of Acute Kidney Injury”.
Therein, Health Canada pointed out that serious kidney or renal problems might be caused by Invokana and Farxiga (known as Forxiga in Canada). While it is not yet confirmed, all of the diabetes drugs in this class, such as Glyxambi, Synjardy, Invokamet, and Xigduo XR, may also be associated with kidney problems.
We are investigating cases of ketoacidosis, kidney damage / renal failure, and other serious side effects of Invokana, Farxiga, Jardiance, and these other newer medications for diabetes as possible drug injury lawsuits against the responsible pharmaceutical companies.
[Read this article in full at original source]
__________________________________________
Invokana / Farxiga / Jardiance
Free Case Evaluation
Strictly Confidential, No Obligation.
___________________________________________
